Viewing Study NCT04627740



Ignite Creation Date: 2024-05-06 @ 3:24 PM
Last Modification Date: 2024-10-26 @ 1:49 PM
Study NCT ID: NCT04627740
Status: RECRUITING
Last Update Posted: 2020-11-13
First Post: 2020-11-05

Brief Title: Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
Sponsor: Xinqiao Hospital of Chongqing
Organization: Xinqiao Hospital of Chongqing

Study Overview

Official Title: A Single-Arm Single-Center Open-Label Pilot Study of Anti-ALPP CART-cells in Patient With Alkaline Phosphatase Placental ALPP-Positive Advanced Solid Tumor
Status: RECRUITING
Status Verified Date: 2024-10
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric antigen receptor CAR-modified T CAR-T cells in treating patients with ALPP-positive Advanced Solid Tumors
Detailed Description: Primary Objectives

To evaluate the number of ALPP-positive participants with treatment-related adverse events as assessed by CTCAE v40 after infusion with anti-ALPP CAR-T cells

Secondary Objectives

The number of patients experience objective response from anti-ALPP CAR-T cells treatment

To evaluate the progression-free survival PFS of anti-ALPP CAR-T cells in patients with ALPP-positive patients

The number and percent of ALPP-CART cells in peripheral blood from ALPP-positive patients at 6 months after infusion

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None